跳至主要内容
临床试验/NCT02949297
NCT02949297已完成不适用

Expanding Patient Applicability With Polymer Sealing Ovation Alto Stent Graft Investigational Device Exemption (IDE) Study

Endologix26 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2017年3月30日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
75
试验地点
26
主要终点
Number of Subjects With Treatment Success

研究概览

简要总结

A prospective clinical evaluation of the effectiveness of the Ovation Alto Abdominal Stent Graft System when used in the treatment of subjects with abdominal aortic aneurysm (AAA).

详细描述

A prospective clinical evaluation of the effectiveness of the Ovation Alto Abdominal Stent Graft System when used in the treatment of subjects with abdominal aortic aneurysm (AAA). The primary objective is to evaluate treatment success at 12 months with the Ovation Alto Abdominal Stent Graft system. The study will have up to 16 sites, and up to 75 patients based on attrition rates. The follow-up intervals will be at 1, 6, and 12 months following initial implant procedure.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Number of Subjects With Treatment Success

时间窗: 12 months

Treatment success is defined as technical success, freedom from type I and III endoleaks at 12 months, freedom from stent graft migration \> 10m at 12 months compared to 1 month baseline, freedom from AAA enlargement \>5mm at 12 months (compared to 1-month baseline, freedom from AAA rupture through 12 months, freedom from conversion to open repair through 12 months, stent graft stenosis, occlusion or kink requiring secondary intervention through 12 months, thromboembolic event attributable to stent graft requiring secondary intervention through 12 months, stent fracture requiring secondary intervention through 12 months.

次要结局

  • Number of Participants With AAA Enlargement > 5mm(6 months, 12 months)
  • Number of Participants With Conversion to Open Repair(30 day, Day 31-365)
  • Number of Participants With AAA-related Mortality(1 month, Day 31-365)
  • Major Adverse Events(1 year)
  • Number of Participants With Other Stent Graft Finding (Includes Kinking and Stent Compression)(1 month, 6 months, 12 months)
  • Number of Participants With Stent Fracture(1 month, 6 months, 12 months)
  • Adverse Events (Serious and Non-serious)(30 days, Day 31-365)
  • Event Rates for Endoleaks(1 month, 6 months, 12 months)
  • Number of Participants With Stent Graft Migration > 10mm(6 months, 12 months)
  • Number of Participants With AAA Rupture(30 day, Day 31-365)
  • Number of Secondary Interventions(30 days, Day 31-365)
  • Device-related Adverse Events (AEs)(30 days, Day 31-365)
  • Procedure-related Adverse Event(30 days, Day 31-365)
  • Serious Adverse Event(30 Days, Day31-365))

研究者

发起方
Endologix
申办方类型
Industry
责任方
Sponsor

研究点 (26)

Loading locations...

相似试验